Biocon Pertuzumab Biosimilar CHMP Positive Opinion
Analysis based on 8 articles · First reported Sep 21, 2026 · Last updated Sep 22, 2026
The positive CHMP opinion strengthens Biocon's biosimilar pipeline and positions it to capture share of the roughly $3.6 billion Pertuzumab market in Europe once International — European Commission approval is granted, a modest positive for Biocon shares. It also signals rising biosimilar competition that could pressure Roche's Perjeta franchise revenue over time, while broadening patient access and potentially lowering treatment costs for HER2-positive breast cancer in the European Union.
Biopharmaceutical, a wholly-owned subsidiary of Biocon, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Union — European Medicines Agency issued a positive opinion recommending marketing authorisation for its Pertuzumab biosimilar, branded Pebrilzo, a 420 mg concentrate solution for infusion for the treatment of HER2-positive breast cancer across multiple disease stages. The application was submitted by Biopharmaceutical Ireland Limited, an indirect wholly-owned subsidiary of Biopharmaceutical. The positive opinion is notable as the first monoclonal antibody biosimilar to receive a positive CHMP opinion under the EMA's tailored clinical development approach, which relies on advanced analytical and clinical pharmacology evidence to establish biosimilarity. The International — European Commission will now conduct the final review and issue its decision; until then the product is not authorised for use in the European Union. The reference biologic, Perjeta, marketed by Roche, reported total sales of over $3.6 billion in 2025. Biocon also recently secured a 10-year supply contract for the breast cancer therapy in Brazil under the country's Productive Development Partnership program. In India, several domestic players including Astec LifeSciences, Abbott Laboratories, Abbott Laboratories and Intas Pharmaceuticals market biosimilar alternatives of the drug.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard